Equities Analysts Offer Predictions for NTLA FY2025 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Analysts at Chardan Capital reduced their FY2025 earnings estimates for Intellia Therapeutics in a research note issued to investors on Monday, November 18th. Chardan Capital analyst Y. Livshits now forecasts that the company will post earnings of ($4.14) per share for the year, down from their previous estimate of ($4.02). Chardan Capital currently has a “Buy” rating and a $91.00 target price on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.13) per share.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $8.28 million. During the same quarter in the prior year, the business posted ($1.38) EPS. The business’s quarterly revenue was down 24.1% on a year-over-year basis.

Several other analysts have also recently issued reports on the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $90.00 target price on shares of Intellia Therapeutics in a research report on Tuesday. The Goldman Sachs Group reduced their target price on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating for the company in a report on Friday, October 25th. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a report on Friday, November 8th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $54.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, September 19th. Finally, Robert W. Baird decreased their target price on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $54.94.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $13.12 on Thursday. The firm has a 50-day simple moving average of $18.40 and a 200-day simple moving average of $21.91. Intellia Therapeutics has a one year low of $12.82 and a one year high of $34.87.

Insider Transactions at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This represents a 4.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in NTLA. Blue Trust Inc. lifted its holdings in Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after purchasing an additional 1,398 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Intellia Therapeutics by 763.5% in the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after acquiring an additional 1,550 shares during the last quarter. Eastern Bank purchased a new stake in shares of Intellia Therapeutics during the third quarter worth approximately $41,000. Values First Advisors Inc. purchased a new position in Intellia Therapeutics in the 3rd quarter valued at $54,000. Finally, First Horizon Advisors Inc. lifted its stake in shares of Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after buying an additional 472 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.